

New Medical Breakthroughs = New Millionaires Who Get In Early



5 Cutting Edge-Medical
Breakthroughs That Can
**Turn Each
\$250 You
Invest Into
\$302,780.00!**

Investors Now Can Make 20 to 50 Times Their Money! (See page 3)

PAGE 4

Killing Infections -- This little-known company has developed super-powerful, hi-tech antibiotics that stop infections when nothing else can.

PAGE 5

Stopping Cancers -- This new test is TWICE as effective at detecting cancer as the current method. It could soon wipe out the number two cancer of women.

PAGE 6

Ending Pain -- This new discovery is poised to turn the \$10 billion pain-killer market upside down.

PAGE 7

Eliminating Fat -- By combining innovative products for weight loss with specifically tailored disease-management solutions, this little-known company is taking the multi-billion dollar diet industry by storm.

PAGE 8

Fighting Cancer and Hepatitis -- This company is on the forefront of strengthening the human immune system to fight cancer and other infectious diseases.

Discover The Life-Saving, Bio-Technology Breakthroughs That Will Help Make You Wealthy From a Very Small Investment ... No Matter What The Stock Market Does!



John deVries,
Editor, Bio-Tech
Breakthrough Stock Report

Dear Friend,

Each \$250 invested in the mid-90s in a medical breakthrough stock named Amgen (AMGN) is now worth a staggering \$302,780,000.

If you want to make extraordinary triple-digit profits no matter what the general economy does (and who doesn't?)... I urge you to mail or fax the form on page 11 today.

ACT
NOW!
YOURS
FREE!

With absolutely NO obligation, I will rush your first profit-packed issue of my exciting **Bio-Tech Breakthrough Stock Report** and begin your RISK-FREE trial subscription at once. And that's not all.

When you reply within the next 10 days, I will also send you my urgent new report, "Little-Known Medical Breakthroughs That Will Make You Rich!" ABSOLUTELY FREE!

As soon as you receive your reports, you will be amazed as I reveal the astonishing cures and medical miracles of tomorrow that little-known, value-priced companies are developing right now.

You will quickly and easily discover how to make a fortune investing in the best of these obscure companies that are pioneers in cutting-edge technology for improving and saving lives.

Most importantly, I will show you how you can stop worrying about the market and make extraordinary profits in any economy like these recent winners:

- ✓ **350% PROFIT** on Ligand Pharmaceuticals (LGND)
- ✓ **417% PROFIT** on Impax Laboratories Inc (IPXL)
- ✓ **503% PROFIT** on Pozen Inc (POZN)
- ✓ **308% PROFIT** on Zila Inc (ZILA)

Huge profits no matter what.

My name is John deVries. Over the years my proven, unique investment research techniques have made enormous profits for myself and my readers.

(Continued on page 4)

Breakthrough Treatment to

KILL THE AIDS VIRUS!

This Stock Has Already Made Investors

565% PROFIT



... And It Will Still Make Investors 20 to 50 Times Their Money!

AIDS is an incurable, deadly killer that must be stopped. According to the United Nations Programme on HIV/AIDS, more than 40 million people are infected with HIV. Every day 14,000 people are infected and 8,000 people die of AIDS. HIV/AIDS has become the fourth most common cause of death in the world.

As you know from President Bush's State of the Union Address, AIDS is a particularly deadly problem in Africa where it is the leading cause of death. Research into the problem by the World Health Organization revealed that the majority of new adult HIV infections were acquired through heterosexual sex.

Armed with that knowledge, a little-known company named Indevus Pharmaceuticals Inc. (IDEV) began developing a topically administered, vaginal microbicide designed to prevent infection by the human immunodeficiency virus (HIV) that causes AIDS. Their product is called PRO2000.

Back in August, shares of IDEV were going for \$1.03 -- ignored by all but the shrewdest investors. Few cared about Indevus or had any idea of this tiny company's potential bio-tech breakthrough. But in June, Indevus announced the start of a Phase II clinical trial of PRO2000 in Africa. Suddenly everyone realized the potential and jumped on the band-wagon.

If you bought \$10,000 worth of IDEV back in August ... it was suddenly worth \$66,504! And PRO2000 has not even completed testing yet. Can you imagine what those shares will be worth if PRO2000 is approved by the FDA as a proven way to stop AIDS?

You don't have to be a rocket scientist to see that a cure for AIDS will be worth billions. Once someone uncovers them, it's easy to identify the medical breakthroughs that will make incredible profits. That's exactly what *Bio-Tech Breakthrough Stock Report* does for you every month. See for yourself. Mail or fax the form on page 11 to start your FREE trial subscription today.

(continued from page 2)

As I scour business and technology for the best, high-profit investments, one trend has come to stand out above all others:

People want relief from sickness and disease in good economies and bad. People want cures for their illnesses whether the DOW is up or down.

When new medical discoveries are made ... when new cures are found ... when new technologies make life better ... people will find ways to buy them no matter what!

And that can mean huge, economy-proof profits for you!

Think about it. While everyone in the media has been crying about the economy for the last couple years, you don't hear the makers of Viagra complaining about sluggish sales. You don't hear makers of the popular, life-saving "statin" drugs like Lipitor reporting that profits are down. And those are just the tip of the ice berg.

Look at these actual profits shrewd investors made on other fast-growing, but still little-known, bio-tech stocks last year:

- ✓ **489% PROFIT** on Able Laboratories (ABRX)
- ✓ **396% PROFIT** on Alaris Medical Systems (AMI)
- ✓ **322% PROFIT** on American Pharmaceutical (APPX)
- ✓ **338% PROFIT** on Bone Care International Inc (BCII)
- ✓ **381% PROFIT** on Columbia Laboratories Inc (COB)

*JUST THE
TIP OF
THE ICE
BERG!*

240% PROFIT

Killing Antibiotic-Resistant "Smart" Bacteria

Bacterial resistance is a serious problem. Over 70% of the bacteria that cause hospital-acquired infections are resistant to at least one of the drugs used to fight them. Tens of thousands of people die each year as a result of resistant infections. And that number is growing exponentially.

Many experts fear unstoppable outbreaks of previously treatable diseases like tuberculosis, staph and strep infections as bacteria develop resistance to the only drugs that can stop them.

Back in September when we discovered little-known Cubist Pharmaceuticals, it was trading at a lazy \$3.99 per share. But our research discovered that this virtual dwarf in the land of pharmaceutical giants was leading a comeback of potent anti-bacterial drugs with its Cidecin.


With Cidecin showing great promise in preliminary trials, CBST shot up to \$13.57 by June -- 240% PROFIT in 9 months! And that's just the beginning.

If the Food and Drug Administration gives final approval for Cidecin as expected, it will be only the second new class of antibiotic approved in 35 years. And if clinical trials testing the drug against endocarditis, a bacterial infection of the heart, pan out, potential sales of Cidecin should exceed \$600 million a year, multiplying company sales by 600 times.



371% PROFIT

Fighting Cancer, Hepatitis and Other Life-Threatening Diseases



The hepatitis C virus is the most common blood-borne disease in the United States - four times more common than AIDS. It is carried by 4 million people in the U.S. and over 170 million world wide.

At least 80% of those with hepatitis C develop chronic liver infection or cirrhosis. It is incurable, and only half of the patients treated respond to current therapies. Hepatitis C is the number 1 cause for liver transplantation in the US.

SciClone Pharmaceuticals, Inc. (SCLN) is a biopharmaceutical company that has risen to the forefront of strengthening the human immune system to fight cancer, hepatitis C and other infectious diseases. SCLN's first drug, Zadaxin, has already been approved by the ministries of health in over 30 countries and is awaiting FDA approval in the U.S. Primary research indicates that Zadaxin may be useful in treating a number of other diseases as well, including hepatitis C, non-small cell lung cancer, melanoma, and HIV/AIDS.

In August, SCLN was trading at barely over \$2/share. Knowledgeable investors rode SCLN to \$9.75 a share in 12 months as word of Zadaxin spread -- a 371% PROFIT -- and it hasn't even been approved in the U.S. yet!

These are the same kind of big-profit breakthroughs you will discover in every monthly issue of my ***Bio-Tech Breakthrough Stock Report***. And here's the best news ...

This is just the beginning! The end of huge bio-tech profits is nowhere in sight!

Consider these facts:

\$\$ There are more than 76 million baby-boomers hitting their 50s at the rate of almost 4 million every year. Their knees hurt, their backs hurt, their cholesterol is high, their prostates hurt, they're going through menopause, they have trouble sleeping, they have Alzheimers, high blood pressure and more. They need medical breakthroughs and they are willing and able to pay for them.

\$\$ \$162 billion will be spent next year on nutritional supplements.

\$\$ \$30 billion a year is spent on new and alternative therapies.

\$\$ More than \$1.3 TRILLION is spent on health care in the U.S. alone every year.

And this money is going to be spent no matter what the stock market does ... no matter what the economy is doing! The profits are there for the taking ... IF you know where to look!

Every month, I do all the research so you know the bio-tech stocks with the hottest, most promising breakthroughs.

With ***Bio-Tech Breakthrough Stock Report*** giving you all the latest inside information on the hottest biotech stocks, your investments will swell with triple-digit profits you can take to the bank like these:

424% PROFIT

Stopping Cervical Cancer: The Number 2 Cancer of Women

Worldwide, cervical cancer affects over 400,000 women annually and, after breast cancer, is the second most common malignancy found in women. According to the American Cancer Society, an estimated 13,000 new cases of invasive cervical cancer will be diagnosed each year and about 4,100 women will die of the disease.



The good news is that cervical cancer is preventable and curable if it is detected early. So, the annual PAP test has become a necessary evil women endure in hopes of stopping this potential killer. The only problem is, studies prove that PAP tests miss more than 50% of the cases.

That's why a little-known medical test-maker, Digene Corp. (DIGE), used cutting-edge technology to develop a new test, the hc2 HR HPV DNA Test, for detecting cervical cancer at its earliest stages. Digene's test, with a 97.8% accuracy rate, virtually makes today's PAP test obsolete.

Back in August, DIGE was trading around \$6.50 a share. But in September, shares of DIGE skyrocketed to \$34.36 -- 424% PROFIT in just 13 months -- when the American College of Obstetricians and Gynecologists revised its guidelines to recommend Digene's cervical cancer test.

Thanks to companies like Digene Corp., we could soon wipe out the number two cancer women face ... and you could make a fortune on this Bio-Tech Breakthrough stock.

- ✓ **163% PROFIT** on **Andrx Corporation (ADRX)**
- ✓ **153% PROFIT** on **Atrix Labs, Inc. (ATRX)**
- ✓ **332% PROFIT** on **Dov Pharmaceutical Inc. (DOVP)**
- ✓ **389% PROFIT** on **Inkine Pharmaceutical Inc. (INKP)**
- ✓ **349% PROFIT** on **Progenics Pharmaceuticals (PGNX)**

Believe me, every penny of these bio-tech profits are 100% real. You can check the stock history yourself. But don't think you can figure out this hi-tech world of bio-tech stocks all by yourself.

The tricky part is identifying the best discoveries. Most people don't have the time or the resources to distinguish the companies that may have the next cure for cancer ... from those which will probably never get off the ground. That's where **Bio-Tech Breakthrough Stock Report** comes in. For example:

- > **Just because a company is popular does not make it a sure stock profit.**

Cellegy Pharmaceuticals (CLGY) became a darling of the popular stock pickers as it rose from \$1.28 a share to \$6.09 on news that its new testosterone gel was submitted for FDA approval. But the approval was denied and the stock dropped like a rock to around \$2 a share. If you jumped on the popular bandwagon and bought CLGY without knowing that approval was unlikely, **you could easily have lost 66% of your investment.**

- > **And just because everyone else gives up on a stock, does not mean it's a loser.**

Flamel Technologies (FLML) was trading at \$1.24 on Wall Street's junk pile in August after its partner abruptly stopped work on Flamel's new injectable technology for long-acting

insulin. But by July FLML got its technology off the ground anyway and it was trading at \$22.90 -- a whopping **1,747% PROFIT!**

 **Your \$10,000 investment would have grown into \$184,700 in just one year!**

The technology is out there. The demand is out there. But to sort the winners from losers, you need to do lots of digging. You need to be on top of the latest technology. You need to know the ins and outs of every business. You need to understand the marketplace. You need to know the people, from top to bottom.

That's exactly the information I sort out and report to you every month in my **Bio-Tech Breakthrough Stock Report**. With **Bio-Tech Breakthrough Stock Report** as your guide, you will know exactly what to buy, what to sell and when to do it for maximum profits.

Discover tomorrow's most exciting medical breakthroughs that will change lives ... and make you rich!

Wouldn't you have liked to know about Viagra two years before it ever came to market? Wouldn't you have liked to invest in that company back then? You better believe it!

Unfortunately, it's too late to jump on that bandwagon. But you CAN invest in the Viagras of tomorrow ... with **Bio-Tech Breakthrough Stock Report**.

Every monthly issue is loaded with tomorrow's bio-tech breakthroughs that are ready for you to discover -- and make your portfolio swell with triple-digit profits.

**YOUR KEY
TO THE
"VIAGRAS" OF
TOMORROW!**

Exciting cures for everything from cancer to the common cold ... Incredible technologies that pin-point medications with laser accuracy ... Powerful therapies that attack diseases on a cellular level ... Advances in nutritional supplements that extend lives ...

The developments that I uncover every month are so exciting you'll have goose-bumps just reading about them. And that's BEFORE you realize how much profit you can make by investing in them.

In fact, readers tell me that their biggest challenge is not in finding a company they want to invest in every month, but in figuring out how to narrow down the excellent choices to fit their investment budget.

405% PROFIT

Ending Pain Without Side Effects

Despite the widespread use of narcotic painkillers, (more than \$3 billion annually) the under-treatment of pain is a serious and growing problem. According to the National Institutes of Health, over 40 million Americans are unable to find relief from their pain. The problem is that conventional narcotic painkillers have debilitating side effects and the potential for addiction that limit their usefulness at all doses.

The small medical research company, Pain

Therapeutics, Inc. (PTIE) in conjunction with The Albert Einstein College of Medicine, is developing a new generation of narcotic painkillers that offer enhanced pain relief while overcoming the problems with conventional narcotic painkillers.



In April shares of PTIE were trading lightly at \$1.68. By July, as word of positive test results, increased testing of additional drugs and potential FDA approval began to surface, PTIE shot up to \$8.48 -- 405% PROFIT in just 3 months!

Bio-Tech Breakthrough Stock Report is your road map to tomorrow's breakthroughs ... and incredible, triple-digit profits ... today!

Wealth and security for you.

All technology stocks are not the same. The bio-tech stocks I recommend are NOTHING like the risky dot-coms of several years ago.



My bio-tech breakthrough stocks are real companies with real products in a real, economy-proof multi-trillion dollar market. That's as close to a sure-bet as you can get.

And with all the research I do, by the time a company is included in ***Bio-Tech Breakthrough Stock Report***, I know it better than just about anyone.

Does this mean every pick is a big winner? Of course not. Sometimes things don't work out the way I expect. But those times are few and far between.

These technologies are so incredible ... the companies are so well researched ... and the applications are so exciting ... you can easily see why my big profit winners far outnumber those that aren't.

And that means with ***Bio-Tech Breakthrough Stock Report***, you can have wealth and security. You can sleep well every night knowing you've invested in rock-solid companies with superior technology in an economy-proof market. It doesn't get any better than that.

Your monthly guide to extraordinary profits.

I summarize all my research every month and deliver every exciting detail to you in my ***Bio-Tech Breakthrough Stock Report***.

1,835% PROFIT Working With Doctors to End Obesity

According to the National Institutes of Health, Americans spend \$33 billion annually on weight-loss products and services. Medifast Inc. (MED) is a rapidly growing company on the cutting edge of weight management and nutrition.

The heart of the Medifast program are meal replacement shakes and other diet products, which are marketed via diet and fitness centers. The Medifast program has been clinically proven at the Johns Hopkins University School of Medicine and has been recommended by over 15,000 physicians. MED also provides wellness and weight management services to corporations.

In August, shares of MED could be had for less than \$1. Medifast recently established a new subsidiary, Take Shape for Life, Inc., which is a national health network of Health Advisor and Healthcare Professionals who provide physician supervised weight and disease management and fitness programs to major clinics, corporations, HMO's, and individuals. In addition, MED recently expanded its product lines to include disease management products. The result: sales and profits skyrocketed ... and so did the price of the stock up to \$17.80 by July. That's 1,835% PROFIT in one year, and the end is nowhere in sight.

MED has terrific operating leverage and has the capacity to grow 5 times to at least \$50 million in annual revenues without the need to make a significant investment in manufacturing equipment.



And while the companies I recommend are hi-tech, my report is not. I purposely write in plain english that anyone can understand. I explain the new technologies in every-day language so you can invest with confidence.

And I don't simply give you a list of stocks and send you on your way. You get all the important details including ...

**INVEST WITH
CONFIDENCE!**

Company and sales information ... industry overview ... stock summary ... performance charts ... current news ... and my own market commentaries based on my research and 17 years of experience ... all to help make it easy for you to decide which of these stocks you want to buy.

Plus, I update the status of every stock I've recommended in every issue. When it's time to sell for maximum profit, you're the first to know. If you passed on a stock when I first recommended it, but are interested now, you'll know if it's still a good buy.

Try *Bio-Tech Breakthrough Stock Report* Risk Free!

I'm so confident that my *Bio-Tech Breakthrough Stock Report* will help you safely and quickly earn extraordinary, triple-digit profits that I want to send it to with ABSOLUTELY NO RISK.

Read *Bio-Tech Breakthrough Stock Report* and discover the bio-technology stocks that will make you big profits ...

If you are not 100% thrilled for any reason, I will send you an immediate, full refund for all unmailed issues. No questions asked.

And that's not all ...



xx% OFF -- Respond within the next 10 days, and I will RUSH your first issue and enter your NO-RISK trial subscription at xx% OFF the regular rate. Plus ...



FREE BONUS! I will also send you my special report, "*Little-Known Medical Breakthroughs That Will Make You Rich!*", **ABSOLUTELY FREE**. You'll discover the bio-tech stocks to buy right now BEFORE they explode with profits.

This FREE BONUS is my way of thanking you for trying *Bio-Tech Breakthrough Stock Report* and it is yours with NO STRINGS ATTACHED. It is yours to keep, no matter what -- even if you cancel your subscription for a no-questions-asked refund.

Don't miss out on the next bio-tech breakthroughs that will make huge profits for smart investors. Don't miss out on the next blockbuster drugs, treatments and cures. Mail or fax the form on page 11 to start your RISK-FREE trial today!

Sincerely,

John DeVries

John DeVries

Editor

P.S. Remember, I will send you my detailed **FREE** report "*Little-Known Medical Breakthroughs That Will Make You Rich!*" when you request a risk-free trial of *Bio-Tech Breakthrough Stock Report* at a huge xx% discount within the next 10 days. It's yours FREE to keep even if you cancel your no-risk trial subscription. Mail or fax the form on page 11 now!

**YOURS
FREE!**

Discover The Medical Breakthroughs of Tomorrow ... Today ... and Make a Fortune!

**Little-Known
Medical
Breakthroughs
That Will Make
You Rich!**

Special FREE Report

**Bio-Tech Breakthrough
Stock Report**

Call or mail the form on page 11 right now to start your risk-free subscription to *Bio-Tech Breakthrough Stock Report*. As our way of saying thanks for your prompt reply, we'll send you this profit-packed bonus report, "Little-Known Medical Breakthroughs That Will Make You Rich!" **ABSOLUTELY FREE!**

Our research team scours the world for the most promising breakthroughs in health care, medicine and biotechnology. In this priceless report you will get all the exciting details you need to stockpile shares of tomorrow's technology ... at today's bargain prices! For example, you'll discover:

A manufacturer whose new packaging technology is becoming the new standard for safety and efficiency in medical facilities throughout the country ... A tiny company mastering advanced polymer technology to deliver medications that has caught the eye of industry giant Pfizer for a huge new application ... The generic drug manufacturers that are ready to hit paydirt with big, new approvals.

New cures for cancer ... amazing ways to pin-point treatments ... incredible technological breakthroughs that will change lives! These are just a few of the daring, new stock winners of tomorrow that you'll discover in this special report TODAY!

To receive your FREE report, just complete the risk-free trial subscription form on page 11 today. This FREE special report is yours to keep ... even if you decide to cancel your subscription at any time. So respond now to cash-in on Bio-Tech Breakthroughs!

YOUR 100% NO RISK SATISFACTION GUARANTEE

If you are not 100% thrilled for any reason, I will send you an immediate, full refund for all unmailed issues. No questions asked. And of course, any issues you received and your free report are yours to keep no matter what!

John DeVries

Mail or Fax This RISK-FREE, "TRYOUT" FORM Now!

YES! I want to become wealthy from a very small investment on the economy-proof, biotechnology breakthroughs of tomorrow!

Please start my NO-RISK trial subscription to the *Bio-Tech Breakthrough Stock Report* and rush me the first issue and my FREE Bonus as checked below. I understand I may receive a refund at any time according to your 100% NO RISK Satisfaction Guarantee.

1 year (12 monthly issues) for only \$XX. That's **XX% OFF** the regular price of \$XXX, and **less than \$X a month!**

Little-Known Medical Breakthroughs That Will Make You Rich!

FAST-REPLY BONUS! I am responding within 10 days. Also send me the BONUS REPORT "*Little-Known Medical Breakthroughs That Will Make You Rich!*" I understand this FREE bonus is mine to keep no matter what -- even if I cancel my subscription.

(Optional): Instead of receiving my monthly newsletters by mail, I would like my newsletters e-mailed to me at: _____

YOURS FREE!

This Special Discount Offer May End Soon -- Please Mail or FAX This Form Today!

Please affix label from back cover here.
If label has been lost or is incorrect, please complete:
Name: _____
Address: _____
City: _____ ST: _____ Zip: _____

METHOD OF PAYMENT

Check or Money Order Enclosed for \$XX (payable to Lombardi Publishing)

Charge my: MasterCard Visa
Card No. _____

Exp Date ___/___/___ Signature _____

**For Fastest Service, FAX this form to:
905-264-9619 24 hours a day**

YOUR 100% NO RISK SATISFACTION GUARANTEE
If you are not 100% thrilled for any reason, I will send you an immediate, full refund for all unmailed issues. No questions asked. And of course, any issues you received and your free report are yours to keep no matter what!
John DeVries

MAIL NOW TO: Lombardi Publishing, 350 Fifth Ave. Suite 3304, New York, NY 10118-0069

Lombardi Publishing Corporation is one of North America's largest financial newsletter companies with over 50,000 customers and growing. Your first newsletter will be rushed out on receipt of your order. See over for important information about our company and this offer. We pride ourselves on excellent customer service.

How The Next Millionaires Will Do It



5 Cutting Edge-Medical
Breakthroughs That
Can
Turn Each
\$250 You
Invest Into
\$302,780.00!

Lombardi Publishing
350 Fifth Avenue, Suite 33604
New York, NY 10118-0069



INSIDE!

**Investors Now Can Make
20 to 50 Times Their
Money! (See page 3)**

[Killing Infection](#) Pg.4

[Stopping Cancer](#) Pg.5

[Ending Pain](#) Pg.6

[Eliminating Fat](#) Pg.7

[PROFIT Fighting Cancer
and Hepatitis](#) Pg 8.

Sample A Sample
Address
City, ST Zip